[Edaily Starin Choi Hee-jae Reporter] Actor Lee Dong-ha shares details of his busy schedule following the success of "Manager Kim." Episode 411 of the MBC variety show “Omniscient Interfering View” (Jeonjamsi), airing on the 15th, depicts the daily life of actor Lee Dong-ha, who played the villain “Manager Nam” in the 2026 blockbuster “Manager Kim.” Lee Dong-ha, who played Director Nam—the right-hand man of the villain Ju Kang-chan (played by Ju Sang-wook)—in the drama “Director Kim,” is set to transform his acting style once again with the play “The Seagull.” The play “The Seagull” is one of Anton Chekhov’s masterpieces and is considered one of Russia’s four greatest plays. Lee Dong-ha takes on the role of the famous novelist “Trygorin.” He completely immerses himself in the role of this sensitive novelist, leaving behind the character of “Director Nam.” During rehearsals alongside distinguished actors such as Jeon Mi-do and Im Cheol-su, he reveals a side of himself that is a complete 180-degree contrast to “Director Nam.” Jeon Mi-do elicits laughter by saying, “When I come to the rehearsal room after watching ‘Director Kim,’ Lee Dong-ha sometimes seems like a different person.” Lim Cheol-soo attests to his unexpected charm, noting, “He’s such a gentle person in everyday life.” Coupled with questions from his colleagues like, “How does it feel to be a star?” this offers a glimpse into the warm and friendly atmosphere of the rehearsal room. Lee Dong-ha also shares wedding tips he learned from Girls’ Day’s Sojin. Lee Dong-ha and Sojin tied the knot in November 2023, and their wedding photos were a major talking point at the time. Lee Dong-ha shares tips for a budget-friendly wedding, ranging from a wedding dress in the 300,000-won range to handmade wedding invitations, reasonably priced wedding rings, and decorating their new home with furniture they already owned. “Jeonjamsi” airs on the 15th at 11:10 p.m.
The slump in the non-investment-grade corporate bond market—which has been centered on BBB-rated bonds this year—is expected to spread to A-rated companies next year. As the burden of issuing corporat…
Amid broader market volatility on Thursday, South Korea’s biopharmaceutical sector lacked a clear directional trend, leaving traditional, profitable pharmaceutical and biotech firms to anchor investor…
A forecast indicates that U.S. production of humanoid robots will reach up to 400,000 units by 2030 and 1.5 million units by 2035. Analysts predict that as the humanoid robot industry moves beyond tec…